The Bone and Joint Infections Market is Forecast to Growth to 2016
GBI research analysis suggests that the global bone and joint infections therapeutics market was worth $0.7 billion in 2009 and this is forecast to grow at a Compound Annual Growth Rate (CAGR) of 8.1% over the next seven years to reach $1.2 billion by 2016. The main reasons for this growth are the rise in the prevalence and diagnosis of bone and joint infections and the increasing use of newly launched antibiotics for the treatment of such infections. However, future market revenue is forecasted to be reduced due to the impact of the patent expiry of Zyvox and Cubicin in 2015 and 2016 respectively. Nevertheless, this impact is expected to be softened by the increase in the revenue contribution of pipeline products for the treatment of complicated bone and joint infections.
Competition among Marketed Products is Strong in the Bone and Joint Infections Therapeutics Market
GBI Research has analyzed the current competitive landscape for bone and joint infections therapeutics drugs and has found the competition to be strong. There are more than 30 types of antibiotics used to treat bone and joint infections. Almost all the marketed products have strong efficacy and good safety profiles. In addition, many generic products, such as penicillins, are available at low cost so therefore there is intense competition in the market.
Quinolones, penicillins, aminoglycosides, carbpenems and many other generics have emerged as the most prescribed antibiotics for bone and joint infections due to their excellent efficacy and safety profiles. They have replaced oxacillins, vancomycin, daptomycin,and third and fourth generation cephalosporins as the first-choice of treatment, despite the latter being recommended as the therapeutic option in the guidelines of major international institutions. The patent expiry of Zyvox and Cubicin may increase the competition in the market. Cephalosporins are expected to capture most of the market available for other generics due to their efficacious advantage.
Efficacy and Safety Profiles of Off-Patent Marketed Products Decreases Market Attractiveness for New Entrants
GBI Research has found that the global bone and joint infections therapeutics market is not very attractive for investors looking to generate significant revenues from the market. The market has highly efficacious drugs with good safety profiles and therefore the currently marketed products meet the needs of most of the patient population. In addition, highly prescribed antibiotics such as quinolones, penicillins, aminoglycosides, cephalosporins, and carbapenems are already available as low cost generics. The unmet needs in the market are very small for investors to capitalize on. These unmet needs are due to the increasing bacterial resistance to the current set of antibiotics. Pharmaceutical companies are therefore focusing on the development of antibiotics for resistant
strains and are most active in this area of clinical development. Molecules that can treat strains resistant to most of the prescribed therapies are expected to cover the unmet needs of the bone and joint infections therapeutics market.
GBI Research, the leading business intelligence provider has released its latest research “Bone and Joint Infection Market to 2016- Medical Imaging and PCR Methods to Facilitate Early Diagnosis and Treatment”, which essentially provides insights on bone and joint therapeutics sales and price forecasts until 2016. The report also examines the global bone and joint infections therapies treatment usage patterns. In addition, the geographical distribution of bone and joint infections therapies across the US, the top five countries in the European region and Japan are also provided in the report. The report also includes insights into the bone and joint infections. The report provides an in-depth analysis of the top three bone and joint infections therapeutic indications, which are prosthetic joint infection, osteomyelitis, and septic arthritis. Furthermore, it also includes the market forecasts and treatment usage patterns of these three therapeutic indications. The report also explores the competitive profiling for top companies. Finally, the key trend analysis on Mergers and Acquisitions (M&As) and licensing agreements involving bone and joint infections therapies is also presented.
It is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.
For further details, please click or add the below link to your browser:
Visit our report store: http://www.gbiresearch.com
For more details contact:
North America: +1 646 395 5477
Europe: +44 207 753 4299
+44 1204 543 533
Asia Pacific: +91 40 6616 6782